Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246662 · ClinicalTrials.gov registry record · Phase 1
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
A Phase 1 study of Myelodysplastic Syndromes and Leukemia, Lymphocytic, Acute, sponsored by Sunesis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 5
- Study locations
NCT00246662 is a Phase 1 study of Myelodysplastic Syndromes and Leukemia, Lymphocytic, Acute that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 75 participants, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (74% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00246662, a Phase 1 study of Myelodysplastic Syndromes and Leukemia, Lymphocytic, Acute, has completed, sponsored by Sunesis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study primarily determined the safety and tolerability of escalating doses of vosaroxin (SNS-595) in 2 dose schedules, and assessed the PK profile of vosaroxin and defined a recommended dose regimen for Phase 2 studies. Secondarily the study assessed potential biomarkers and antileukemic activity.
Conditions Studied
Interventions
- DRUG Vosaroxin
Study Locations (5)
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Indiana
- Indiana University Cancer Center - Indianapolis
Maryland
- Johns Hopkins Hospital - Baltimore
New Mexico
- New Mexico Cancer Care Alliance - Albuquerque
Texas
- University of Texas, MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2005-11-14 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246662
The ClinicalTrials.gov registry entry for NCT00246662 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 285-participant average among 173 other Myelodysplastic Syndromes trials with a reported enrollment target (74% lower). The listed sponsor is Sunesis Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which Vosaroxin is the first listed.
NCT00246662 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Indiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT00246662 about?
NCT00246662 is a clinical study titled "Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies". This study primarily determined the safety and tolerability of escalating doses of vosaroxin (SNS-595) in 2 dose schedules, and assessed the PK profile of vosaroxin and defined a recommended dose regimen for Phase 2 studies. Secondarily the study assessed potential biomarkers and antileukemic activi...
What is the current status of trial NCT00246662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2005-11-14. Estimated completion is 2009-04.
What conditions does trial NCT00246662 study?
This clinical trial studies the following conditions: Myelodysplastic Syndromes, Leukemia, Lymphocytic, Acute, Leukemia, Myeloid, Chronic, Leukemia, Nonlymphocytic, Acute.
What interventions are being tested in trial NCT00246662?
The interventions under investigation include: Vosaroxin (DRUG).
Who is sponsoring clinical trial NCT00246662?
This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00246662 being conducted?
This trial has 5 study locations across Florida, Indiana, Maryland, New Mexico, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
RECRUITING · Phase 1
-
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.